Innovative Technology Platform Garuda Therapeutics is developing a proprietary platform for off-the-shelf, durable blood stem cells, which positions them to disrupt traditional transplant therapies and meet urgent patient needs with consistent, ready-to-use solutions.

Active Funding Opportunities The recent $50 million Series A-1 funding and the earlier $62 million Series B investment highlight ongoing investor confidence, providing potential avenues for partnership, co-development, or clinical trial support.

Strategic Partnerships Garuda’s collaboration with Be The Match BioTherapies indicates an openness to partnerships that can accelerate commercialization and adoption of their blood stem cell therapies within the transplant ecosystem.

Leadership and Expertise The appointment of experienced executives including a new CEO and a Chief Scientific Officer suggests a strong leadership team capable of driving research advancement and fast-tracking product development, opening doors for collaborations.

Market Expansion Potential With a technology poised to address over 120 diseases and plans to provide rapid access to therapies, Garuda presents significant sales opportunities across hematology, oncology, and regenerative medicine markets.